Photo: Cryptographer/Shutterstock
On Thursday, Brazil’s federal health regulatory body Anvisa authorized the first prophylactic Covid-19 drug for use in Brazilians with immune problems (such as cancer patients or people who have received organ transplants) or who are contraindicated to take vaccines.
The antibody treatment, produced by AstraZeneca and sold under the brand name Evusheld, is engineered to be metabolized more slowly so it can stay active for months — perhaps for half a year.
Evusheld has already obtained regulatory approval in the U.S., France, Israel, Italy, Bahrain, Egypt, and the United Arab Emirates. The drug is the seventh anti-Covid treatment approved in Brazil.
In 2000, Formula 1 great Michael Schumacher had just racked up his 41st race win,…
Overall, the worldwide economic outlook has improved according to the Organization for Economic Co-operation and…
“This is f***ing corruption, it has to change,” protested an irate John Textor, owner of…
Eduardo Leite, governor of the southern Brazilian state of Rio Grande do Sul, on Wednesday…
Moody’s is the latest rating agency to improve its assessment of Brazil, bumping up the…
Other finalists include the Harvard Business Review, Fortune, Condé Nast, and the NFL